You are here

New Indication for Pemetrexed In Metastatic NSCLC

Trial Demonstrated Significantly Improved Survival Rates

Pemetrexed for injection (Alimtra, Eli Lilly and Company) has received FDA approval for a new indication in combination with pembrolizumab (Keytruda, Merck) and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. 

The approval was based on data from the phase 3 KEYNOTE-189 trial, which enrolled patients regardless of PD-L1 expression and had primary endpoints of overall survival (OS) and progression-free survival (PFS).  

KEYNOTE-189 demonstrated that Alimta, in combination with pembrolizumab plus platinum-based chemotherapy, resulted in significantly longer OS and PFS than ALIMTA plus platinum chemotherapy with placebo. 

Severe adverse reactions occurring in ≥20% of patients included fatigue, diarrhea, dyspnea, vomiting, nausea, rash, decreased appetite, constipation, and pyrexia.

Source: Eli Lilly and Company, January 31, 2019

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs